The abstract is read at the publisher; the summary is JClub's.
Higher post-booster HLA-aware Spike-reactive T cell breadth (HA-TS) predicts lower risk of symptomatic SARS-CoV-2 infection during the Delta and Omicron waves in the UK, HR 0.58 (95% CI 0.39–0.86).
- Why it matters: HLA-driven differences and constraints of live T cell functional assays limit how well vaccination trials can quantify cell-mediated immunity and identify correlates of protection.
- What they did: In COV-BOOST (third-dose trial, 2021–2022, United Kingdom), the team estimated HA-TS breadth from participants’ HLA genotypes, TCRβ repertoires, and an S HLA-linked reference catalog, then related it to symptomatic infection risk.
- The result: The HA-TS breadth–symptomatic infection association remained after adjusting for neutralizing antibody titers and IFN-γ responses, and cross-study comparisons suggest HA-TS tracks genotype, exposure intensity, and time since exposure.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.